ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3084

The Impact of Mental Health on Indicators of Disease Severity Among Patients with Inflammatory Arthritis: A Cross-Sectional and Longitudinal Investigation

Renee El-Gabalawy1, Mathew Bernstein2, Cory Mackenzie3, Jitender Sareen4 and Carol Hitchon5, 1Clinical Health Psychology and Anesthesia & Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada, 2Clinical Psychology, University of Manitoba, Winnipeg, MB, Canada, 3Psychology, University of Manitoba, Winnipeg, MB, Canada, 4Psychiatry, University of Manitoba, Winnipeg, MB, Canada, 5University of Manitoba, Winnipeg, MB, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: psychological status and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Rheumatoid arthritis, is the leading cause of disability and chronic pain. Psychiatric disorders such as depression and anxiety adversely impact reported pain and may also be influenced by systemic inflammation. We conducted a comprehensive, longitudinal investigation to assess the association of depressive and anxiety disorders, including severity of symptoms, with subjective and physician-assessed indicators of arthritis severity among outpatients with recent onset inflammatory arthritis.

Methods: Data included 148 subjects (mean age = 57.7, 72% female) from a prospective longitudinal Early Arthritis Cohort (<12 months symptoms at baseline) from 2012 to 2015. Presence of anxiety or depressive disorder was indicated via self-report annually, and severity of psychiatric symptoms was assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) scales each visit. Arthritis activity indicators included patient reported visual analogue scales for pain fatigue, and functional status (modified health assessment questionnaire; mHAQ), physician global disease activity, swollen 28 joint count, tender 28 joint count, Lansbury weighted joint count, erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and composite indices (DAS28ESR-3variable, Clinical Disease Activity Index (CDAI)). Patients were re-assessed at each visit (visit range = 1 thru 7 visits, median (IQR) months followed 18(11,22)). Linear regressions and bivariate and partial correlations (controlling for number of visits and presence of a current mood or anxiety disorder for symptom-based analyses) first examined the cross-sectional relationship between mental health variables and indicators of arthritis severity. Linear regressions controlling for number of visits examined the longitudinal relationship between change in mental health symptoms on indicators of arthritis severity. Only results significant at the 0.01 level are reported to adjust for multiple comparisons.

Results: The presence of a current mood or anxiety disorder was reported by 10.7% and 6.3%, respectively, of the cohort at any time. Fatigue was associated with both a mood disorder (Beta = 0.27, t (202) = 4.025, p < 0.001) and anxiety disorder (Beta = 0.197, t (197) = 2.814, p < 0.01). Increasing severity of anxiety and depressive symptoms were significantly associated with pain, fatigue, CDAI, tender joint count, mHAQ and the Lansbury index (r range = 0.156-0.514). Severity of depressive symptoms were associated with ESR, DAS28 and CRP. When controlling for the presence of a mood or anxiety disorder and number of visits, most associations remained statistically significant. Worsening of anxiety (Beta = 0.212, t (314) = 3.85, p < 0.001) and depressive symptoms (Beta = 0.207, t (314) = 3.75, p< 0.001) over time were significantly associated with CRP values.

Conclusion: Indicators of disease severity were impacted by mental health factors, particularly severity of chronic pain and fatigue. Severity of mental health symptoms were a better indicator of disease severity than the presence of a psychiatric disorder alone. These findings have important implications for screening, prevention, and treatment.


Disclosure: R. El-Gabalawy, University of Manitoba, 2; M. Bernstein, None; C. Mackenzie, None; J. Sareen, None; C. Hitchon, Health Sciences Centre Foundation, Manitoba Health Research Council, 2.

To cite this abstract in AMA style:

El-Gabalawy R, Bernstein M, Mackenzie C, Sareen J, Hitchon C. The Impact of Mental Health on Indicators of Disease Severity Among Patients with Inflammatory Arthritis: A Cross-Sectional and Longitudinal Investigation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-mental-health-on-indicators-of-disease-severity-among-patients-with-inflammatory-arthritis-a-cross-sectional-and-longitudinal-investigation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-mental-health-on-indicators-of-disease-severity-among-patients-with-inflammatory-arthritis-a-cross-sectional-and-longitudinal-investigation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology